# South Korea Preclinical Imaging Market

> South Korea Preclinical Imaging Market Research Report By Product (Optical Imaging, Nuclear Imaging, Micro-MRI, Micro-Ultrasound, Micro-CT, Photoacoustic Imaging System) and By Distribution Channel (Optical, Nuclear, CT Contrast Agents, MRI Contrast Agents) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.25%
- **2024:** $ 124.25 Million
- **2025:** $ 133.26 Million
- **2035:** $ 268.29 Million
- **Key Players:** Bruker Corporation (US), PerkinElmer Inc. (US), Siemens Healthineers (DE), GE Healthcare (US), Philips Healthcare (NL), Miltenyi Biotec (DE), Mediso Medical Imaging Systems (HU), Fujifilm VisualSonics (CA), Aspect Imaging (IL)

**Report ID:** MRFR/MED/48496-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-preclinical-imaging-market-50253

---

## Market Summary

## **South Korea Preclinical Imaging Market Overview**

As per MRFR analysis, the South Korea Preclinical Imaging Market Size was estimated at 115.5 (USD Million) in 2023. The South Korea Preclinical Imaging Market Industry is expected to grow from 124.25(USD Million) in 2024 to 310.26 (USD Million) by 2035. The South Korea Preclinical Imaging Market CAGR (growth rate) is expected to be around 8.675% during the forecast period (2025 - 2035)

**Key South Korea Preclinical Imaging Market Trends Highlighted**

The growth of the South Korea Preclinical Imaging Market can be attributed to increased spending on R&D alongside technological advancement. South Korea has strategically focused on biotechnology by providing various government initiatives for advanced innovations in health and life sciences. There is now wider use of imaging modalities like MRI, PET, and CT in Preclinical research, which aids in improving the accuracy and efficacy of drug development processes. Important to note is how digital transformation is influencing the market, which is due to the embedment of AI and machine learning in imaging technologies.

These efforts are focused on the unique data analysis and detection requirements of South Korean research facilities. There is also a growing collaboration between the universities and the private sector which helps accelerate the setting up of the new imaging technologies. A surge in the number of local companies providing preclinical imaging solutions, on the other hand, is very positive, especially with regard to the new export opportunities to other parts of Asia or niche markets for specific therapeutic areas.

As further developed imaging approaches are required to aid researchers in understanding disease mechanisms and treatment responses, the demand for sophisticated imaging techniques increases along with the demand for personalized medicine.

Recently, there has been a trend toward the use of integrated multimodal imaging, where two or more imaging techniques are used together as they add value to understanding a biological process. It integrates South Korea's regulatory agencies, has been more flexible with the newly adopted imaging modalities, and expedites the approval processes, which accelerates access to the market. In addition, funding for the infrastructure of sophisticated imaging center facilities is also increasing, which funds the preclinical research and developmental project work in the area.

Thus, With supportive government policies and dynamic research, South Korea is set to lead in the preclinical imaging market in the coming years.

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South Korea Preclinical Imaging Market Drivers**

**Increasing Investments in Research and Development**

The South Korea Preclinical Imaging Market Industry is poised for significant growth due to increasing investments in Research and Development (R&D) activities. The South Korean government has designated biotechnology and healthcare as key sectors for national development, leading to a substantial increase in public and private funding. According to the Ministry of Science and ICT, the government plans to invest an additional 2 trillion KRW in healthcare innovation, which is aimed at enhancing the capabilities of local companies in developing advanced imaging technologies.

This substantial financial backing will facilitate advancements in preclinical imaging technologies and improve overall healthcare outcomes, positioning South Korea as a leader in biomedical research and drug development. Major organizations such as Samsung Medical Center and Korea University Medical Center are engaged in pioneering research that frequently relies on preclinical imaging technologies, further emphasizing the importance of this driver in the growth of the South Korea Preclinical Imaging Market Industry.

**Rising Incidence of Chronic Diseases**

The increasing prevalence of chronic diseases in South Korea serves as a significant driver for the South Korea Preclinical Imaging Market Industry. With reports indicating a 12% rise in chronic disease cases over the past six years, including diseases such as cancer and diabetes, healthcare providers are increasingly relying on advanced imaging techniques to enhance diagnostics and therapeutic monitoring. The Korean Center for Disease Control and Prevention highlights that ailments like cancer have an estimated incidence rate of around 300,000 new cases annually.

This growing patient demographic necessitates the need for advanced preclinical imaging tools to support early diagnosis and personalized treatment plans, ultimately driving market growth. Contributing organizations such as the Korea Cancer Society play a fundamental role in advocating for cutting-edge technology in medical research, further amplifying the demand for effective imaging solutions.

**Technological Advancements in Imaging Modalities**

Rapid technological advancements in imaging modalities are acting as a crucial catalyst for the expansion of the South Korea Preclinical Imaging Market Industry. Innovations in imaging technologies such as Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Computed Tomography (CT) are enhancing the accuracy and efficacy of preclinical studies. The Korea Institute of Industrial Technology reported that advancements in imaging resolution and capabilities have led to enhanced imaging techniques that can reveal minute biological processes.

With local companies like LS Electronics investing heavily in these technologies, and collaborations with universities for technology transfer, the South Korea Preclinical Imaging Market Industry is set for robust growth. These advancements not only aid in the understanding of disease mechanisms but also streamline the development timelines for new drugs and therapies.

**Increase in Public-Private Partnerships**

The establishment of public-private partnerships (PPPs) is significantly influencing the South Korea Preclinical Imaging Market Industry. These collaborations enhance resource sharing risk mitigation and accelerate innovation in preclinical imaging technologies. The Korean government, in collaboration with major industry players like SK Telecom, has initiated programs aimed at developing smart healthcare technologies that include preclinical imaging systems.

The Ministry of Health and Welfare's strategic directions align well with industry objectives, enabling more efficient use of resources in research. These partnerships are projected to facilitate the development and commercialization of novel imaging solutions, thereby contributing to the overall market growth. As these entities leverage their collective strengths, the South Korea Preclinical Imaging Market Industry will benefit from enhanced technological advancements and increased market competitiveness.

**South Korea Preclinical Imaging Market Segment Insights**

**Preclinical Imaging Market Product Insights**

The South Korea Preclinical Imaging Market is playing a crucial role in enhancing the understanding of various biomedical processes, with the Product segment showcasing significant diversity in its offerings. Among the various imaging modalities, Optical Imaging is gaining attention for its non-invasive methods that allow for real-time visualization of cellular processes, making it invaluable for cancer research and drug development. This modality leverages fluorescent proteins and dyes, which provide detailed insights into biological mechanisms, thus driving advancements in Research and Development efforts within the country. 

Nuclear Imaging, on the other hand, is critical for its ability to visualize physiological and biochemical processes in vivo an essential tool in pharmacological studies and the investigation of disease mechanisms, thereby supporting regulatory approvals in the pharmaceutical sector. Micro-MRI stands out in its unique capacity to provide high-resolution imaging of small animal models, which is vital for neuroscience and oncology studies. The ongoing research in South Korea's medical technology sector emphasizes the importance of this method in understanding therapeutic responses at a microscale, ultimately leading to more targeted treatment options. 

Micro-, recognized for its safety and versatility, is facilitating advances in prenatal and cardiac research by providing exceptional detail for soft tissue imaging, which is essential for early diagnosis and monitoring development in animal models. Micro-CT is another key player, particularly in the field of preclinical veterinary medicine and cancer research, where it offers high spatial resolution insights into bone structure and pathology. This technology allows for detailed 3D visualization, aiding in surgical planning and tracking disease progression in small animal studies.

Photoacoustic Imaging System, which combines optical and ultrasound imaging techniques, is further revolutionizing the landscape by offering remarkable contrast based on tissue composition. 

This modality is seeing increased adoption for its potential to provide molecular imaging capabilities, thus enhancing the specificity of cancer diagnostics.Overall, each of these segments within the South Korea Preclinical Imaging Market is contributing to the overall advancement of biomedical research, fostering opportunities for innovation while addressing various challenges faced in drug development and disease understanding. As these imaging technologies evolve, they are becoming increasingly integrated into the workflows of research laboratories across the nation, significantly impacting the future of healthcare solutions in South Korea.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Preclinical Imaging Market Distribution Channel Insights**

The South Korea Preclinical Imaging Market is characterized by a diverse Distribution Channel that plays a crucial role in determining the accessibility and effectiveness of imaging solutions to various stakeholders in the research and clinical fields. Within this market segment, Optical and Nuclear imaging techniques are significant for their precision in visualizing biological processes, which aids in advancing research and development within the biotechnology and pharmaceutical industries. 

Meanwhile, CT Contrast Agents and MRI Contrast Agents play a pivotal role in enhancing the quality of imaging results, thereby enabling more accurate diagnostics and therapeutic monitoring.The emphasis on innovative imaging technologies is driven by the growing demand for advanced and reliable preclinical studies to support the burgeoning biotechnology sector in South Korea. As the government continues to invest in Research and Development initiatives, the market is set to benefit from increased collaboration among academic institutions and industry players. 

Furthermore, regulatory support for technological advancements and a focus on enhancing imaging accuracy align with public health goals, positioning the South Korea Preclinical Imaging Market for robust growth in the forthcoming years.

**South Korea Preclinical Imaging Market Key Players and Competitive Insights**

The South Korea Preclinical Imaging Market is witnessing a dynamic landscape driven by advancements in imaging technologies and an increasing focus on research and development in the life sciences sector. This market has seen significant growth due to the rising demand for accurate and reliable imaging solutions that can streamline drug discovery and development processes. With the proliferation of innovative methodologies such as molecular imaging and multimodal imaging systems, stakeholders are keenly aware of the competitive dynamics at play.

As players strive to establish their foothold, understanding the strengths and capabilities of key participants is crucial for driving market strategies and collaborations.

Elekta has established a strong market presence in the South Korea Preclinical Imaging Market, leveraging its cutting-edge technologies and innovative systems. The company is known for its commitment to providing advanced imaging solutions that enhance precision in preclinical studies. Elekta's strengths lie in its strong research and development capabilities, which enable continuous advancement in imaging technologies tailored to meet the specific needs of the South Korean research community. The company's focus on collaboration with local research institutions and its adaptability to regional regulatory requirements further solidify its position in the market. 

This local engagement helps Elekta understand the unique needs of South Korea researchers while fostering partnerships that can lead to groundbreaking innovations in preclinical imaging.GAMMATEC is positioned as a notable player in the South Korea Preclinical Imaging Market, with a portfolio of products that includes high-quality imaging systems and associated software solutions. The company has developed strong relationships with local academic institutions and research organizations, which bolsters its market presence and credibility in the region. GAMMATEC's strengths are evident in its ability to provide tailored imaging solutions that address the specific challenges faced by researchers in South Korea. 

The company is dedicated to innovation and often engages in strategic partnerships that enhance its product offerings. In recent times, GAMMATEC has expanded its reach through targeted mergers and acquisitions, allowing it to integrate new technologies and capabilities that benefit its customer base in South Korea. This strategic approach positions GAMMATEC favorably in an increasingly competitive environment where the demand for sophisticated preclinical imaging solutions continues to grow.

**Key Companies in the South Korea Preclinical Imaging Market Include**

**South Korea Preclinical Imaging Market Industry Developments**

In recent developments within the South Korea Preclinical Imaging Market, significant advancements have been noted, particularly as companies like GE Healthcare and Siemens Healthineers enhance their imaging technologies to support research in drug development and disease modeling. These innovations are crucial in light of the growing demand for precise imaging techniques in preclinical studies. Notably, Merck KGaA has made strides in expanding its preclinical imaging portfolio, responding to the increasing investment in biotechnology and pharmaceutical sectors in South Korea. 

Additionally, in September 2023, PerkinElmer announced a partnership with a local institution aimed at boosting the application of preclinical imaging technologies in cancer research, showcasing collaborative efforts to advance medical science. Over the past two to three years, the South Korean government has prioritized healthcare technology, fostering an environment conducive to growth in the preclinical imaging sector, with an expected market valuation increase driven by R&D expansion initiatives from major companies like Canon and Bruker.

Notably, market dynamics are also influenced by acquisitions and mergers, though no recent major mergers have been reported among the companies of interest within this specific domain in South Korea.

**South Korea Preclinical Imaging Market Segmentation Insights**

## Market Drivers

### Emerging Applications in Disease Modeling

Emerging applications of preclinical imaging in disease modeling are reshaping the landscape of biomedical research in South Korea. Researchers are increasingly utilizing imaging technologies to study complex diseases, such as cancer and neurodegenerative disorders, in animal models. This trend is driven by the need for better understanding of disease mechanisms and the development of targeted therapies. The preclinical imaging market is expected to grow as these applications gain traction, with an anticipated increase in market size by 10% over the next five years. This evolution highlights the critical role of imaging in advancing medical research.

### Rising Demand for Non-Invasive Techniques

The preclinical imaging market in South Korea experiences a notable surge in demand for non-invasive imaging techniques. Researchers and pharmaceutical companies increasingly prefer methods that minimize animal suffering while providing accurate data. This shift is driven by ethical considerations and regulatory pressures, leading to a growing adoption of modalities such as MRI and PET. The market is projected to expand as these technologies become more accessible and affordable, with an estimated growth rate of 8.5% annually. This trend indicates a significant transformation in research methodologies, emphasizing the importance of humane practices in preclinical studies.

### Collaboration Between Academia and Industry

The preclinical imaging market benefits from increasing collaboration between academic institutions and industry players in South Korea. Partnerships facilitate the exchange of knowledge and resources, driving advancements in imaging technologies. Universities are often at the forefront of research, while companies provide the necessary funding and infrastructure. This synergy is expected to yield innovative imaging solutions, enhancing the overall quality of preclinical studies. As a result, the market may witness a compound annual growth rate (CAGR) of around 7% over the next few years, indicating a healthy ecosystem for research and development.

### Growing Focus on Drug Development Efficiency

Efficiency in drug development processes is becoming a critical driver for the preclinical imaging market in South Korea. As pharmaceutical companies strive to reduce time-to-market for new therapies, the integration of advanced imaging techniques is essential. These technologies enable real-time monitoring of drug efficacy and safety in preclinical models, streamlining the research process. The market is likely to expand as organizations recognize the value of imaging in accelerating drug discovery, with projections suggesting a growth rate of 6% annually. This focus on efficiency underscores the evolving landscape of pharmaceutical research.

### Increased Investment in Research and Development

Investment in research and development (R&D) within South Korea significantly influences the preclinical imaging market. The government and private sectors are channeling substantial funds into biomedical research, fostering innovation in imaging technologies. In 2025, R&D expenditure in the life sciences is expected to reach approximately $5 billion, reflecting a commitment to advancing healthcare solutions. This influx of capital is likely to enhance the capabilities of imaging modalities, leading to improved diagnostic accuracy and efficiency in preclinical studies. Consequently, the preclinical imaging market is poised for robust growth as new technologies emerge.

## Future Outlook

The [Preclinical Imaging Market](https://www.marketresearchfuture.com/reports/preclinical-imaging-market-7365) in South Korea is projected to grow at a 7.25% CAGR from 2025 to 2035, driven by technological advancements and increasing R&D investments.

**New opportunities:**

- Development of AI-driven imaging software solutions
- Expansion of imaging services in contract research organizations
- Partnerships with biotech firms for tailored imaging solutions

By 2035, the preclinical imaging market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Product: Optical Imaging (Largest) vs. Nuclear Imaging (Fastest-Growing)

In the South Korea preclinical imaging market, Optical Imaging holds the largest share among the various product segments, reflecting its broad application in biological imaging and real-time observation of cellular processes. Other segments, such as Nuclear Imaging and Micro-MRI, also play significant roles in this market, but they do not eclipse the dominance of Optical Imaging in terms of market presence and utilization.

The growth trends in this market indicate a rising demand for advanced imaging techniques, particularly due to the increasing focus on early-stage drug development and personalized medicine. Nuclear Imaging has emerged as the fastest-growing segment, driven by technological advancements and the need for precise imaging modalities that enhance diagnostic capabilities for preclinical studies. This growth is further supported by the expanding research activities in universities and research institutions.

Optical Imaging (Dominant) vs. Nuclear Imaging (Emerging)

Optical Imaging is recognized as the dominant force in the South Korea preclinical imaging market, characterized by its high-resolution capabilities and non-invasive nature, ideal for tracking biological processes in real time. Its applications span across various fields, including drug discovery and developmental biology, making it a preferred choice for researchers. Conversely, Nuclear Imaging, while still emerging, is gaining traction due to its ability to provide functional imaging through radiopharmaceuticals. This segment benefits from advancements in detector technologies and data analysis techniques, positioning it as a critical tool in disease detection and treatment evaluation. Together, these segments illustrate the dynamic evolution of imaging technologies in the preclinical research landscape.

### By Reagents: Optical (Largest) vs. MRI Contrast Agents (Fastest-Growing)

In the South Korea preclinical imaging market, the Optical reagents segment dominates with a significant market share, driven by their widespread application in various imaging techniques. Following closely, MRI Contrast Agents are emerging as an important player due to their increasing utilization and technological advancements that enhance their effectiveness. Both segments are pivotal in offering researchers innovative solutions for visualizing biological processes.

The growth trends in the South Korea preclinical imaging market are largely attributed to ongoing research in biotechnology and pharmaceuticals, alongside a rising demand for non-invasive imaging techniques. Optical reagents are benefitting from advancements in fluorescence technologies, while MRI Contrast Agents are gaining momentum due to developments in patient-specific imaging solutions, which are critical in the diagnosis and monitoring of diseases. This combination of innovation and necessity is propelling both segments forward, ensuring robust growth in the coming years.

Reagents: Optical (Dominant) vs. MRI Contrast Agents (Emerging)

Optical reagents are considered the dominant force in the South Korea preclinical imaging market, owing to their established use in procedures like fluorescence microscopy and imaging in live cell environments. They are highly favored for their sensitivity and specificity, enabling researchers to gain deeper insights into cellular functions. In contrast, MRI Contrast Agents represent an emerging segment, rapidly gaining traction due to the advancement of imaging technologies that improve resolution and diagnostic capabilities. The ability of MRI contrast agents to facilitate enhanced visual clarity in soft tissues positions them as vital tools for researchers focusing on tumor detection and other critical applications, showcasing a substantial shift towards more sophisticated imaging modalities.

## Competitive Benchmarking

The preclinical imaging market in South Korea is characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for innovative imaging solutions. Key players such as Bruker Corporation (US), Siemens Healthineers (DE), and GE Healthcare (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Bruker Corporation (US) focuses on innovation, particularly in developing high-resolution imaging systems that cater to the needs of researchers in drug discovery and development. Siemens Healthineers (DE) emphasizes partnerships with academic institutions to foster research and development, thereby enhancing its product offerings. GE Healthcare (US) is actively pursuing regional expansion, aiming to strengthen its foothold in the Asia-Pacific market through localized manufacturing and tailored solutions.
The competitive structure of the market appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. This strategy not only improves responsiveness to market demands but also aligns with the growing trend of sustainability in manufacturing processes. The collective influence of these key players shapes a competitive environment where innovation and operational excellence are paramount.
In October 2025, Siemens Healthineers (DE) announced a strategic partnership with a leading South Korean university to develop advanced imaging technologies tailored for preclinical research. This collaboration is expected to leverage academic expertise and accelerate the development of cutting-edge imaging solutions, thereby enhancing Siemens' competitive edge in the market. The partnership underscores the importance of academic collaborations in driving innovation and meeting the evolving needs of researchers.
In September 2025, GE Healthcare (US) launched a new line of preclinical imaging systems designed specifically for small animal studies. This launch is significant as it addresses the growing demand for high-throughput imaging solutions in preclinical research. By focusing on this niche, GE Healthcare aims to capture a larger share of the market and solidify its position as a leader in preclinical imaging technologies.
In August 2025, Bruker Corporation (US) unveiled a novel imaging modality that integrates AI algorithms to enhance image analysis and interpretation. This development is particularly noteworthy as it reflects the increasing integration of artificial intelligence in imaging technologies, which could potentially revolutionize the way researchers analyze preclinical data. Bruker's commitment to innovation through AI positions it favorably in a market that is rapidly evolving towards more sophisticated imaging solutions.
As of November 2025, current trends in the [preclinical imaging](https://www.marketresearchfuture.com/reports/preclinical-imaging-market-7365)market indicate a strong shift towards digitalization and AI integration, with companies increasingly focusing on sustainability and operational efficiency. Strategic alliances, such as those between industry players and academic institutions, are shaping the competitive landscape by fostering innovation and enhancing product offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, reliability in supply chains, and the ability to deliver tailored solutions that meet the specific needs of researchers.

## Recent News & Developments

In recent developments within the South Korea Preclinical Imaging Market, significant advancements have been noted, particularly as companies like GE Healthcare and Siemens Healthineers enhance their imaging technologies to support research in drug development and disease modeling. These innovations are crucial in light of the growing demand for precise imaging techniques in preclinical studies. Notably, Merck KGaA has made strides in expanding its preclinical imaging portfolio, responding to the increasing investment in biotechnology and pharmaceutical sectors in South Korea. 

Additionally, in September 2023, PerkinElmer announced a partnership with a local institution aimed at boosting the application of preclinical imaging technologies in cancer research, showcasing collaborative efforts to advance medical science. Over the past two to three years, the South Korean government has prioritized healthcare technology, fostering an environment conducive to growth in the preclinical imaging sector, with an expected market valuation increase driven by R&D expansion initiatives from major companies like Canon and Bruker.

Notably, market dynamics are also influenced by acquisitions and mergers, though no recent major mergers have been reported among the companies of interest within this specific domain in South Korea.

## Report Scope

| MARKET SIZE 2024 | 124.25(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 133.26(USD Million) |
| MARKET SIZE 2035 | 268.29(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.25% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Bruker Corporation (US), PerkinElmer Inc. (US), Siemens Healthineers (DE), GE Healthcare (US), Philips Healthcare (NL), Miltenyi Biotec (DE), Mediso Medical Imaging Systems (HU), Fujifilm VisualSonics (CA), Aspect Imaging (IL) |
| Segments Covered | Product, Reagents |
| Key Market Opportunities | Advancements in imaging technologies enhance drug development efficiency in the preclinical imaging market. |
| Key Market Dynamics | Technological advancements drive innovation in preclinical imaging, enhancing research capabilities and regulatory compliance in South Korea. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What was the overall market valuation of the preclinical imaging market in 2024?**
A: The overall market valuation was $124.25 Million in 2024.

**Q: What is the projected market valuation for the preclinical imaging market in 2035?**
A: The projected valuation for 2035 is $268.29 Million.

**Q: What is the expected CAGR for the preclinical imaging market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period is 7.25%.

**Q: Which companies are considered key players in the preclinical imaging market?**
A: Key players include Bruker Corporation, PerkinElmer Inc., Siemens Healthineers, GE Healthcare, Philips Healthcare, Miltenyi Biotec, Mediso Medical Imaging Systems, Fujifilm VisualSonics, and Aspect Imaging.

**Q: What were the revenue figures for Optical Imaging in 2024?**
A: In 2024, Optical Imaging generated revenues of $15.0 Million.

**Q: How much revenue is projected for Micro-CT by 2035?**
A: Micro-CT is projected to generate revenues of $60.0 Million by 2035.

**Q: What was the revenue for Nuclear Imaging in 2024?**
A: Nuclear Imaging had a revenue of $20.0 Million in 2024.

**Q: What are the projected revenues for MRI Contrast Agents by 2035?**
A: MRI Contrast Agents are projected to reach revenues of $98.29 Million by 2035.

**Q: What revenue did Photoacoustic Imaging Systems achieve in 2024?**
A: Photoacoustic Imaging Systems achieved revenues of $24.25 Million in 2024.

**Q: What is the expected growth trend for the preclinical imaging market in South Korea?**
A: The market is expected to grow steadily, with a projected CAGR of 7.25% from 2025 to 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-preclinical-imaging-market-50253*